H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CYTK stock, giving a Buy rating today.Stay Ahead of the ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...

By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...

The clinical-stage biotechnology company backed by investors like Nvidia and Roche welcomed Michael Secora to the team.

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal ...